Companies › Trevi Therapeutics
1 active drug program in 8 registered trials: 4 Phase 4, 2 Phase 3, 2 Phase 2; Neurology, Gastroenterology, Other, Respiratory; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nalbuphine Opioid receptors; mu/kappa/delta agonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute … | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07435337 | Nalbuphine | Phase 4 | Laryngoscopy | Other | May 2026 |
| NCT07271849 | Nalbuphine | Phase 4 | Postoperative Pain, Acute | Neurology | Oct 2026 |
| NCT07613801 | Nalbuphine | Phase 4 | Hip Fracture Surgeries | Other | Nov 2026 |
| NCT06037330 | Nalbuphine | Phase 4 | Acute Respiratory Distress Syndrome | Respiratory | Nov 2026 |
| NCT06996561 | Nalbuphine | Phase 2 | Cholecystectomy | Gastroenterology | Jan 2027 |
| NCT07868419 | Nalbuphine | Phase 3 | Idiopathic Pulmonary Fibrosis | Respiratory | Aug 2027 |
| NCT07671924 | Nalbuphine | Phase 2 | Refractory Chronic Cough | Other | Sep 2027 |
| NCT07671911 | Nalbuphine | Phase 3 | Idiopathic Pulmonary Fibrosis | Respiratory | Jun 2028 |
Cash and short-term investments of $299m on 2026-09-30; operating cash outflow about $72m a year; runway about 50 months at that burn, to Nov 2030; 4 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ardelyx GRIN Therapeutics Adneuris Therapeutics AgelessRx Palvella Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.